Pseudoephedrine Use in Third Trimester Pregnancy

Safety Profile and Risk-Benefit Considerations

• Oral decongestants should ideally be avoided during the first trimester due to conflicting reports of associations with congenital malformations such as gastroschisis and small intestinal atresia 1
• The risk of pseudoephedrine use appears substantially lower than NSAIDs, which are absolutely contraindicated in the third trimester due to serious fetal risks including premature closure of the ductus arteriosus, oligohydramnios, and pulmonary hypertension 2
• The American College of Allergy and Clinical Immunology suggests that pseudoephedrine use is likely safer than many other medications when short-term use is absolutely necessary for severe nasal congestion, with the European Heart Journal recommending use only when nasal congestion is severe enough to significantly impact maternal quality of life or sleep 1
• The European Heart Journal recommends limiting pseudoephedrine use to the lowest effective dose for the shortest duration possible, ideally single doses or 1-3 days maximum 2
• Saline nasal irrigation and humidification are recommended as first-line alternatives to pseudoephedrine by the European Heart Journal 4
• Women with pre-existing hypertension or preeclampsia should avoid pseudoephedrine entirely due to its vasoconstrictive effects, according to the European Heart Journal 4
• The combination of pseudoephedrine with acetaminophen or salicylates may increase malformation risks, though this data comes from first-trimester exposures, as reported by the Journal of Allergy and Clinical Immunology 1